Drug pricing reform has become one of the most discussed strategies for controlling Medicaid costs. As states face rising enrollment, increasing healthcare expenditures, specialty medications, and growing program complexity, policymakers are searching for ways to reduce spending without compromising access to care.
One of the latest efforts is the Centers for Medicare & Medicaid Services’ (CMS) GENEROUS Model, which seeks to lower Medicaid drug costs by negotiating supplemental rebates and encouraging states and manufacturers to participate in a framework designed to achieve better pricing. While the initiative has the potential to generate savings, many questions remain regarding participation, implementation, and the overall magnitude of its financial impact.
The reality is that Medicaid cannot afford to rely on any single cost-containment strategy.
Even if drug pricing reforms ultimately succeed, states will continue to lose billions of dollars each year due to preventable payment errors, inaccurate eligibility data, and coordination of benefits failures that occur long before rebate calculations ever enter the equation.
The Immediate Opportunity States Already Have
Drug pricing reforms require federal action, manufacturer participation, state adoption, and time.
Payment prevention can begin immediately.
Every day, Medicaid programs pay claims for beneficiaries whose coverage information is incomplete, outdated, or simply unknown at the time of adjudication. When commercial insurance exists but is not identified, Medicaid often pays claims as the primary payer when another insurer should have been billed first.
These payments are frequently categorized as improper payments, not because fraud occurred, but because the correct coverage information was unavailable when the claim was processed.
Why Prevention Matters More Than Recovery
Many organizations still rely heavily on recovery efforts, commonly referred to as “pay and chase.”
While recoveries remain an important component of program integrity, they address improper payments only after resources have already left the program.
More importantly, recovery does not change the fact that an improper payment occurred.
Federal payment accuracy measurements evaluate whether claims were paid correctly at the time of adjudication. If Medicaid lacked accurate coverage information when the claim was processed, the payment may still count against program accuracy metrics even if funds are recovered later.
This distinction is becoming increasingly important as states face growing pressure to improve payment accuracy and reduce improper payment rates.
The most effective dollar is the dollar that never leaves the Medicaid program unnecessarily.
The Hidden Cost of Unknown Coverage
One of the largest and most persistent challenges facing Medicaid programs is unknown commercial coverage.
Coverage can change constantly throughout the year as beneficiaries:
- Start new jobs
- Change employers
- Gain dependent coverage
- Lose coverage
- Get married
- Move between Medicaid and commercial plans
- Experience eligibility redeterminations
In many cases, commercial coverage becomes active long before Medicaid systems are aware of the change.
This creates a gap between reality and what is visible inside eligibility systems.
During that gap, Medicaid may continue paying claims that should have been coordinated with another insurer or avoided entirely.
The result is a steady stream of preventable expenditures that accumulate across millions of claims.
Cost Avoidance Delivers Immediate Results
Unlike policy initiatives that may require years to implement, payment prevention strategies can produce measurable savings immediately.
When states improve eligibility verification, identify unknown coverage sooner, and maintain more accurate TPL data, claims can be redirected before payment occurs.
The benefits are immediate:
- Reduced improper payments
- Improved payment accuracy
- Lower recovery costs
- More effective coordination of benefits
- Better compliance with federal requirements
- Stronger program integrity outcomes
Most importantly, these savings do not depend on future legislation, manufacturer participation, or federal demonstration projects. They are available today.
Drug Pricing Reform and Payment Prevention Are Not Competing Strategies
The discussion should not be framed as drug pricing reform versus program integrity.
Medicaid needs both.
Pricing reform may help reduce the cost of certain medications and improve purchasing efficiency. Those initiatives deserve attention and evaluation.
However, lower drug prices alone cannot solve the broader problem of preventable spending. Nor are they the only means of dramatically improving program efficiency.
A claim paid with incorrect eligibility information is still an improper payment regardless of how much the medication costs.
A coordination of benefits failure still represents avoidable spending regardless of rebate levels.
Unknown commercial coverage still creates financial leakage regardless of future pricing reforms.
States that focus exclusively on reducing prices while overlooking payment prevention leave significant savings on the table.
The Path Forward
As Medicaid programs search for sustainable cost-containment strategies, the greatest opportunities often exist within processes that already influence every claim.
Improving eligibility accuracy, identifying unknown coverage, strengthening coordination of benefits, and preventing improper payments before they occur can deliver measurable savings immediately.
While policymakers continue to evaluate long-term initiatives such as the GENEROUS Model, Medicaid agencies and managed care organizations do not need to wait for future reforms to begin improving financial performance.
The technology, data sources, and operational strategies needed to identify coverage earlier and prevent improper payments already exist.
The most effective cost avoidance strategy is not simply paying less for healthcare services.
It is preventing Medicaid from paying claims that should never have been paid in the first place.
Drug pricing reform may ultimately help reduce certain categories of Medicaid spending, but it cannot address every source of financial leakage within the program. Accurate eligibility data, timely identification of third-party liability, stronger coordination of benefits, and proactive payment prevention remain some of the fastest and most effective ways to improve program integrity and protect Medicaid dollars. While policymakers continue to pursue long-term reforms, Medicaid agencies and managed care organizations can achieve measurable savings today by preventing improper payments before they occur.
